SCHEMBL5065372

SCHEMBL5065372

COc1ccc(CN(C)c2cc3c(cn2)cc(-c2ccc(F)c(N)c2)c(=O)n3-c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 5/20 0.42
LYN P07948 3/20 0.42
SRC P12931 3/20 0.42
ALDH1A1 P00352 6/20 0.39
USP2 O75604 5/20 0.39
CYP1A2 P05177 5/20 0.39
CASP1 P29466 3/20 0.39
CASP7 P55210 3/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
BRCA1 P38398 1/20 0.39
HBB P68871 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GNRHR P30968 6/20 0.37
CYP3A4 P08684 3/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422436 0.85 FGFR4 (0.42) BTKLYNSRCALDH1A1CYP1A2
SCHEMBL15272719 0.77 ALDH1A1 (0.43) SRCALDH1A1HSD17B10KMT2AADORA2A
SCHEMBL15006322 0.77 BTK (0.44) BTKLYNSRCALDH1A1ADORA2A
SCHEMBL4566697 0.77 FGFR1 (0.39) BTKLYNSRCALDH1A1KDM4E
SCHEMBL14999907 0.76 BTK (0.41) BTKLYNSRCALDH1A1
SCHEMBL16632663 0.76 ALDH1A1 (0.40) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL5062666 0.76 FGFR1 (0.38) BTKLYNSRCALDH1A1KDM4E
SCHEMBL4426075 0.75 BTK (0.46) BTKLYNSRCALDH1A1USP2
SCHEMBL14999841 0.75 BTK (0.41) BTKLYNSRCALDH1A1
SCHEMBL4431201 0.75 BTK (0.53) BTKLYNSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BTK 492/4885LYN 428/4885SRC 417/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BTK 492/4885LYN 428/4885SRC 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.